HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company’s latest multi-center U.S. Phase 2 study of its proprietary drug NX-1207 for the treatment of benign prostatic hyperplasia (BPH) is nearing completion. The Company anticipates the reporting of final results and statistical analysis for the study within the next few weeks.
